ClinicalTrials.gg
CompletedNCT06229145Updated Sep 17, 2026Results posted

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

A Phase 4 interventional study of Pegloticase and Methotrexate in Gout, sponsored by Amgen. Completed at 74 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
Largest of 14
306 · median 93
Started
2024
the only one that year
Phase 4
7 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one has the largest enrollment, is the only one that started in 2024, is one of 7 in phase 4, and was the 13th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout.

The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.

Read the detailed description

Acquired from Horizon in 2024.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Uncontrolled Gout
  • pegloticase
  • Krystexxa
  • Methotrexate
  • Chronic Gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult men or women ≥ 18 years of age
  2. Uncontrolled gout, defined as meeting the following criteria:

    • Hyperuricemia during the Screening Period, defined as sUA ≥ 7 mg/dL, and;
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a to xanthine oxidase inhibitor therapy based on medical record review or participant interview, and;
    • Symptoms of gout
  3. Willing to discontinue any oral ULT for at least 7 days prior to MTX dosing at Week -4 and continue not receiving any oral ULT when receiving pegloticase/placebo for pegloticase infusions
  4. Women of must have negative serum/urine pregnancy tests during screening and Week -4.
  5. Men who are not vasectomized must agree to use appropriate , so as to not impregnate a female partner of during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis
  2. Current or chronic treatment with systemic agents, such as MTX, azathioprine or mycophenolate mofetil; prednisone > 10 mg/day or equivalent dose of other on a chronic basis (3 months or longer)
  3. History of any transplant surgery requiring maintenance immunosuppressive therapy
  4. Known history of virus surface antigen positivity or hepatitis B DNA positivity
  5. Known history of virus RNA positivity, unless treated and viral load is negative
  6. Known history of (HIV) positivity
  7. G6PD deficiency (quantitative test at the Screening Visit centrally or locally)
  8. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina) or uncontrolled blood pressure (> 160/100 mmHg) prior to Week -4
  9. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner or not on an effective form of , as determined by the Investigator
  10. Prior treatment with pegloticase, another recombinant uricase (rasburicase) or concomitant therapy with a PEG-conjugated drug
  11. Unable to tolerate MTX 15 mg orally during the MTX Run-in Period
  12. Chronic liver disease
  13. White blood cell count \< 4,000/μL, hematocrit \< 32% or count \< 75,000/μL
  14. Currently receiving systemic or radiologic treatment for ongoing cancer
  15. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix
  16. Diagnosis of osteomyelitis
  17. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome
  18. A known intolerance to all protocol-standard gout flare prophylaxis regimens (i.e., participant must be able to tolerate at least 1 of the following: colchicine and/or non-steroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day)
  19. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    Pegloticase + Methotrexate Q4W

    16 mg pegloticase will be administered intravenously every 4 weeks for 24 weeks during double blind treatment and 24 weeks during open label.

    Biological: Pegloticase · Drug: Methotrexate

  • Experimental
    Pegloticase + Methotrexate Q2W

    8 mg pegloticase will be administered intravenously every 2 weeks for 24 weeks during double blind treatment and 16 mg pegloticase every 4 weeks for 24 weeks during open label.

    Biological: Pegloticase · Drug: Methotrexate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

    Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during Month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.

    Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)

Secondary outcomes

  1. Percentage of Participants With Complete Resolution of ≥ 1 Tophus at Week 24 in Participants With Tophi at Baseline

    Time frame: Baseline, Week 24

07

Results

Posted Jul 1, 2026

Participant flow

Participants were enrolled at 51 trial centers in United States of America from 18 March 2024. The primary analysis data is presented for the double-blind period up to 30 July 2025, with a database snapshot date of 26 September 2025; the trial is ongoing, and data from the open-label period will be posted with the final analysis. A 4 week methotrexate (MTX) run in period with weekly dose of 15 mg was used to identify screening failures due to MTX intolerance.

Run-in Period
Participant flow — Run-in Period
MilestoneMTX Run-In Period: All ParticipantsPegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTX
Started30600
Completed26200
Not completed4400
Withdrew: Unable to tolerate mtx900
Withdrew: Inclusion criteria not met1900
Withdrew: Exclusion criteria met1100
Withdrew: Inclusion criteria not met and exclusion criteria met100
Withdrew: Various reasons400
Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneMTX Run-In Period: All ParticipantsPegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTX
Started0130131
Received at least 1 dose of pegloticase0130131
Completed0113113
Not completed01718
Withdrew: Lost to follow-up022
Withdrew: Participant decision01516

Outcome measures

PrimaryPercentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during Month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.

Time frame:
Month 6 (Weeks 20, 21, 22, 23, and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
percentage of participantsPegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTX
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 670.8 (62.2 to 78.4)56.5 (47.6 to 65.1)
Statistical analysis
  • Pegloticase 8mg Q2W + MTX vs Pegloticase 16mg Q4W + MTX · Regression, Logistic · p = 0.10 · Response rate difference: 12.7 · 95% CI 1.2 to 24.1
SecondaryPercentage of Participants With Complete Resolution of ≥ 1 Tophus at Week 24 in Participants With Tophi at Baseline
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

Adverse events

Collected over For all-cause mortality: from signing of inform consent form (ICF) through database lock (DBL) for primary analysis (up to Week 24); For Serious adverse events and other adverse events: from first dose of MXT through DBL for the primary analysis (up to Week 24).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MTX Run-In Period: All Participants0/306 (0%)2/306 (0.7%)61/306 (19.9%)
Pegloticase 8mg Q2W + MTX0/130 (0%)4/130 (3.1%)66/130 (50.8%)
Pegloticase 16mg Q4W + MTX0/131 (0%)9/131 (6.9%)87/131 (66.4%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventMTX Run-In Period: All ParticipantsPegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTX
Anaphylactic reactionImmune system disorders0/3061/1303/131
Haemolytic anaemiaBlood and lymphatic system disorders0/3061/1300/131
Obstructive pancreatitisGastrointestinal disorders0/3061/1300/131
PyelonephritisInfections and infestations0/3061/1300/131
Atrial fibrillationCardiac disorders0/3060/1301/131
Cardiac failure congestiveCardiac disorders1/3060/1301/131
Herpes zosterInfections and infestations0/3060/1301/131
PneumoniaInfections and infestations0/3060/1301/131
Pneumonia influenzalInfections and infestations0/3060/1301/131
Orthostatic hypotensionVascular disorders0/3060/1301/131
Most frequent other events
Most frequent other events
EventMTX Run-In Period: All ParticipantsPegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTX
GoutMetabolism and nutrition disorders61/30662/13081/131
ArthralgiaMusculoskeletal and connective tissue disorders0/30610/1303/131
Infusion related reactionInjury, poisoning and procedural complications0/3069/1309/131

Baseline characteristics

The Full analysis set (FAS) included all participants who received at least 1 dose of pegloticase.

Age, Continuous
Age, Continuous(years)Pegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTXTotal
Mean56.4 ± 10.653.2 ± 11.654.8 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTXTotal
Female7613
Male123125248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTXTotal
Hispanic or Latino5855113
Not Hispanic or Latino6770137
Unknown or Not Reported5611
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegloticase 8mg Q2W + MTXPegloticase 16mg Q4W + MTXTotal
American Indian or Alaska Native123
Asian6814
Black or African American302050
Multiple101
Native Hawaiian or Other Pacific Islander011
White91100191
Other101
08

Study locations

74 sites
  • The University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35233, United States
  • Orthopedic Physicians Alaska - Rheumatology and Infusion
    Anchorage, Alaska 99508-5234, United States
  • Arizona Arthritis and Rheumatology Associates - Chandler
    Chandler, Arizona 85225-2915, United States
  • Arizona Arthritis and Rheumatology Rese
    Flagstaff, Arizona 86001, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Gilbert, Arizona 85297, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85032, United States
  • Arizona Arthritis and Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Arizona Arthritis and Rheumatology Research, PLLC
    Phoenix, Arizona 85037-4403, United States
  • Arizona Arthritis and Rheumatology Research
    Phoenix, Arizona 85037, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Sun City, Arizona 85351, United States
  • Arizona Arthritis and Rheumatology
    Tucson, Arizona 85704, United States
  • Covina Arthritis Clinic
    Covina, California 91722, United States
  • Medvin Clinical Research- Riverside
    Hemet, California 92543, United States
  • Velocity Clinical Research - Boise - ERN - PPDS
    North Hollywood, California 83642, United States
  • TriWest Research Associates
    San Diego, California 92108, United States
  • Precision Comprehensive Clinical Research Solutions
    San Leandro, California 94578-2630, United States
  • Saint John's Health Center - Providence St John's Health Ctr
    Santa Monica, California 90404, United States
  • C.V. Mehta MD Medical Corporation
    Temecula, California 92592, United States
  • Foothill Arthritis
    Tujunga, California 91042, United States
  • Medvin Clinical Research
    Whittier, California 90602, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Lynn Institute of the Rockies
    Colorado Springs, Colorado 80918, United States
  • Denver Arthritis Clinic - Rheumatology
    Denver, Colorado 80230, United States
  • Arthritis & Rheumatic Disease
    Aventura, Florida 33180-1204, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • Life Clinical Trials
    Margate, Florida 33063-5675, United States
  • Homestead Associates in Research,Inc
    Miami, Florida 33032-8225, United States
  • D&H National Research Centers, Inc.
    Miami, Florida 33155, United States
  • Well Pharma
    Miami, Florida 33173, United States
  • Felicidad Medical Research, LLC.
    Miami, Florida 33184, United States
  • New Generation Of Medical Research
    Naples, Florida 34104, United States
  • IRIS Research & Development
    Plantation, Florida 33324, United States
  • D&H Pompano Research Center
    Pompano Beach, Florida 33064, United States
  • D&H Tamarac Research Center
    Tamarac, Florida 33321, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • ClinPro Research Solutions, LLC
    Tampa, Florida 33613, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • Vista Clinical Research, LLC
    Newnan, Georgia 30265, United States
  • Great Lakes Clin. Trials
    Chicago, Illinois 60625, United States
  • Conquest Research - Anesthesiology/Pain Medicine
    Chicago, Illinois 60637, United States
  • Great Lakes Clinical Trials - Gurnee
    Highland Park, Illinois 60035, United States
  • Crowley CORE - Illinois Bone and Joint Institute
    Hinsdale, Illinois 60521, United States
  • Lake Cumberland Rheumatology, PLLC
    New Albany, Indiana 47150, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Velocity CR - New Orleans
    Covington, Louisiana 70433, United States
  • Velocity CR - New Orleans
    New Orleans, Louisiana 70121-2429, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • June DO,PC
    Lansing, Michigan 48911, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
  • Velocity Clinical Research-Vestal
    Vestal, New York 13850, United States
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28226, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • Triad Clinical Trials - Gastroenterology
    Greensboro, North Carolina 27410, United States
  • Accellacare of Hickory
    Hickory, North Carolina 28602, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451-4168, United States
  • Shelby Clinical Research - Family Medicine
    Shelby, North Carolina 28152, United States
  • Velocity Clinical Research- Cincinatti
    Cincinnati, Ohio 45242, United States
  • Velocity Clinical Research - Cleveland
    Cleveland, Ohio 44122, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73111-3324, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Velocity Clinical Research, Spartanburg - Pulmonology
    Greenville, South Carolina 29615, United States
  • Premier Clinics Pa - Rock Hill, Sc
    Rock Hill, South Carolina 29732, United States
  • Low Country Rheumatology
    Summerville, South Carolina 29486-7887, United States
  • Amarillo Center for Clinical Research, Ltd.
    Amarillo, Texas 79124, United States
  • Clinical Trial Network
    Austin, Texas 78750, United States
  • Synergy Groups Medical LLC
    Houston, Texas 77061, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • AIM Trials - Internal Medicine
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • Velocity Clinical Research - Salt Lake City (West Jordan)
    West Jordan, Utah 84088, United States
  • Velocity Clinical Research-Portsmouth
    Portsmouth, Virginia 23703-3200, United States
  • Arthritis Northwest, PLLC - Research
    Spokane, Washington 99204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2025, 16 months.

Results were first posted in Jul 2026, 11 months after primary completion.

Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartActual
Mar 18, 2024
Primary completionActual
Jul 30, 2025
CompletionActual
Mar 26, 2026
Results first posted
Jul 1, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06229145
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Mar 18, 2024
Primary completion
Jul 30, 2025
Completion
Mar 26, 2026
Results posted
Jul 1, 2026
Last update
Sep 17, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion